{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT04397796",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "InterventionArmGroupLabel",
                  "InterventionBrowseBranchAbbrev",
                  "InterventionBrowseBranchName",
                  "InterventionBrowseLeafAsFound",
                  "InterventionBrowseLeafId",
                  "InterventionBrowseLeafName",
                  "InterventionBrowseLeafRelevance",
                  "InterventionDescription",
                  "InterventionMeshId",
                  "InterventionMeshTerm",
                  "InterventionName",
                  "InterventionOtherName",
                  "InterventionType",
                  "IsFDARegulatedDevice",
                  "IsFDARegulatedDrug",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "InterventionArmGroupLabel": [
                              "BM-Allo.MSC",
                              "Placebo"
                        ],
                        "InterventionBrowseBranchAbbrev": [
                              "PhSol",
                              "All"
                        ],
                        "InterventionBrowseBranchName": [
                              "Pharmaceutical Solutions",
                              "All Drugs and Chemicals"
                        ],
                        "InterventionBrowseLeafAsFound": [],
                        "InterventionBrowseLeafId": [
                              "M85407"
                        ],
                        "InterventionBrowseLeafName": [
                              "Plasma-lyte 148"
                        ],
                        "InterventionBrowseLeafRelevance": [
                              "low"
                        ],
                        "InterventionDescription": [
                              "BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.",
                              "plasmalyte and human albumin"
                        ],
                        "InterventionMeshId": [],
                        "InterventionMeshTerm": [],
                        "InterventionName": [
                              "BM-Allo.MSC",
                              "Placebo"
                        ],
                        "InterventionOtherName": [],
                        "InterventionType": [
                              "Biological",
                              "Biological"
                        ],
                        "IsFDARegulatedDevice": [
                              "No"
                        ],
                        "IsFDARegulatedDrug": [
                              "Yes"
                        ],
                        "NCTId": [
                              "NCT04397796"
                        ]
                  }
            ]
      }
}